ASH 2014

Frontline Chemoimmunotherapy with Fludarabine/Cyclophosphamide/Rituximab versus Bendamustine/Rituximab in Advanced CLL: Final Analysis of the CLL10 Study

Conference Correspondent - ASH 2014 - CLL

For physically fit patients with chronic lymphocytic leukemia (CLL) with low comorbidity burden, the combination of fludarabine, cyclophosphamide, and rituximab (FCR) is the standard frontline regimen. CLL10 was a randomized, multicenter, international, phase 3 study designed to evaluate the efficacy [ Read More ]